Drug
Centanafadine
Centanafadine: highest development phase Phase 3, developed by Otsuka. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| Centanafadine XR NCT07759154 | Phase 3 | Attention-deficit/Hyperactivity Disorder |
| Centanafadine Hydrochloride NCT05257265 | Phase 3 | Attention-Deficit/Hyperactivity Disorder |
| Centanafadine NCT04081363 | Phase 2 | Attention Deficit Hyperactivity Disorder |
| Centanafadine NCT04786730 | Phase 1 | Attention-deficit Hyperactivity Disorder |
Latest
No recent events.
Follow Centanafadine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.